http://www.oxford-instruments.com/Pages/home.aspx


Oxford Instruments is a leading provider of high technology tools and systems for research and industry. We design and manufacture equipment that can fabricate, analyse and manipulate matter at the atomic and molecular level.

Oxford Instruments has discrete business groups operating in three sectors. This means we can focus our expertise, our technologies and our innovation on offering our customers high quality products and service that meet their stringent requirements.







Financial Calendar


Half Year/Interim Results Announcement

Tuesday November 13th 2012 : 9.30am The London Stock Exchange

Annual General Meeting:

Tuesday 11th September 2012 : 2.30pm

Oxford Instruments plc, Tubney Woods, Abingdon, Oxon OX13 4QX

26 September 2012 Ordinary shares quoted ex-dividend
28 September 2012 Record date for final dividend
30 September 2012 DRIP date
25 October 2012 Payment of final dividend
March 2013 Ordinary shares quoted ex-dividend
Dividend reinvestment (DRIP) last date for election
Record date for interim dividend
31 March 2013 Financial Year End

Pre-close Trading Update

RNS


RNS Number : 4651E

Oxford Instruments PLC

10 April 2014






Release Date: 10 April 2014





Pre-close Trading Update





Oxford Instruments plc, a leading provider of high technology tools and systems for industry and research, is today issuing a trading statement ahead of entering its close period.



As anticipated, there was a strong trading performance in the last quarter. The integration of Andor Technology is proceeding to plan and has aided the results; however this has been offset by the strength of sterling against our main trading currencies. As a result we reiterate the guidance given in our February IMS that we expect performance for the year to be in-line with the prior year.



Oxford Instruments' preliminary results for the year ended 31 March 2014 will be released on Tuesday 10 June.



Ends

Final results Tues 10 June

Final Results

RNS


RNS Number : 2050J

Oxford Instruments PLC

10 June 2014






Release Date: 7am Tuesday 10 June 2014



Oxford Instruments plc

Announcement of Preliminary Results for the year to 31 March 2014



Oxford Instruments plc, a leading provider of high technology tools and systems for industry and research, today announces its Preliminary Results for the year to 31 March 2014.



Highlights:



· Orders grew by 2.5% to £342.2 million (2013: £334.0 million)

· Revenue grew by 2.7% to £360.1 million (2013: £350.8 million); 4.3% on a constant currency basis

· Adjusted profit before tax* of £47.1 million (2013: £47.0 million)

· Adjusted operating margin* of 14.0% (2013: 14.1%), in line with 14 Cubed objectives

· Adjusted EPS* up 1.8% at 67.7 pence (2013: 66.5 pence)

· Andor Technology acquisition integrating well and performing ahead of plan

· Investment in R&D, up 11.2% to £27.9 million (2013: £25.1 million)

· Proposed final dividend of 9.04 pence (2013: 8.15 pence), giving a total dividend for the year of 12.4 pence (2013: 11.2 pence)

· Strategy seeks to exploit the convergence of the sciences which will enhance demand for nanotechnology tools

*Adjusted numbers are stated to give a better understanding of the underlying business performance. Details of adjusting items can be found in Note 1.



Jonathan Flint, Chief Executive of Oxford Instruments plc, said:



"The Group delivered another successful result, with orders, sales and profits all ahead of the prior year. We are very pleased to welcome Andor to Oxford Instruments and see the acquisition as an important part of the next phase of our growth.



We will continue to focus on developing innovative new products and growing market share in our core areas of physical science. In addition, we will seek to extend our reach into adjacent new markets by applying our tools and technologies to life science research and analysis.



This convergence of the sciences will enhance long term demand for our nanotechnology tools and enable us to reach a new set of customers working in the nano-bio arena."

11 Jun JP Morgan... 1,750.00 Overweight

16 Jun N+1 Singer 1,445.00 Hold

Share tips: 'Why I am backing Oxford Instruments'

Each week we look at a promising mid-cap share. This week: Oxford Instruments, which makes hi-tech equipment for scientific research

Part Of The Atlas Experiment Equipment: How the universe evolved from a liquid

Oxford Instruments only makes around 9pc of its revenue in the UK, making it vulnerable to the strength of the pound Photo: REX FEATURES


By Kyle Caldwell

6:13PM BST 03 Jul 2014




Oxford Instruments, which makes hi-tech equipment for scientific research, has suffered of late from a drop in demand from government-funded projects. But this has not led all investors to rush for the exits.


One fund manager who remains a fan is Chris Murphy, who runs the Aviva Investors UK Equity Income fund. He said that despite a 27pc fall in the share price this year he would remain a long-term holder.


“The firm has an unloved status following pressures of government spending cuts and the effects of a strong pound,” he said. “But having met with the firm last month I came away with the impression of a business turning a corner and a management team with a plan.”


The plan involves focusing on developing new products while keeping an eye on potential acquisitions to expand the business. Oxford Instruments has bought several firms in recent years, the latest being Andor Technology, which it bought for £158m in January.


“The firm’s market-leading products mean that the shares continue to justify premium pricing relative to peers,” Mr Murphy said.


“An improving global outlook should see a return to research funding, while issues such as the horsemeat scandal have led to a dramatic increase in food testing and the need for better technology.”

Interim Management Statement

RNS


RNS Number : 3969M

Oxford Instruments PLC

16 July 2014






Release date: 16 July 2014



Oxford Instruments plc

Interim Management Statement





Oxford Instruments plc, a leading provider of high technology tools and systems for industry and research, today issues an Interim Management Statement which covers the period from 1 April 2014 to date.

Orders in the first quarter of the year were above the same period last year despite the worsening foreign exchange environment. This was on both a reported and constant currency organic basis.

On a constant currency basis, orders were ahead of the same period last year in our major trading regions of Europe, North America and Asia. Excluding Andor, acquired in January 2014, orders were ahead in North America but lagged in Europe and Asia.

The integration of Andor continues to progress and its performance was slightly ahead of expectations in the first three months of the year.

Our broad spread of geographies and technologies and our strong pipeline of new products continue to underpin the long term prospects for the Group. The Board anticipates that Oxford Instruments will continue to make progress in line with its expectations for the remainder of the financial year.

Save as described in this statement, there has been no significant change in the financial position of the Group in the period.

Beaufort Securities - Oxford Instruments (LOL:OXIG)

Yesterday, Oxford Instruments announced that it expects an enhanced second half owing to better year to date order intake compared to the previous year on a reported and constant currency basis. The company concluded its 14Cubed plan in June and realized a return of 14% on sales and an annually compounded revenue increase of 11% over a period of three years. The successful integration with Andor, acquired in January this year, also helped strengthen the order book in North America and Europe for nanotechnology tools and industrial products. On a separate note, the company announced the retirement of Sir Michael Brady and the appointment of Sir Richard Friend to the board. The stock rose 3.1% in yesterday’s trade.

Our view: The improved order book of Oxford Instruments is well indicative of the robust revenues that could be achieved by the company in this fiscal. Barring a few hiccups from the Asian markets, the company expects to leverage its brand equity and distribution network in the ever expanding market for its products. Oxford Instruments continued efforts to enhance operational efficiencies to focus on convergence of the nano-bio sciences along with strategic acquisitions give the company a good upside potential. We retain a Buy rating for the stock.

Shares - We see scope to surprise on the upside as conditions improve into 2015.

13 Oct Investec 1,405.00 Buy

Interim results Tues 11 Nov

Half Yearly Report

RNS


RNS Number : 6598W

Oxford Instruments PLC

11 November 2014






Release Date: 7am Tuesday 11th November 2014



Oxford Instruments plc

Announcement of Half Year Results for 2014/2015



Oxford Instruments plc, a leading provider of high technology tools and systems for industry and research, today announces its Half Year Results for the six months to 30 September 2014.



Highlights:



· First half orders up 19.9% to £201.5 million (2013: £168.0 million); on a constant currency organic basis, orders up 7.4%.

· First half revenue up 7.3% to £178.5 million (2013: £166.3 million); on a constant currency organic basis revenues down 5.9%.

· Adjusted operating profit* of £18.9 million (2013: £22.0 million).

· Adjusted EPS of 20.9 pence (2013: 28.6 pence).

· Andor Technology acquisition integrating well and performing ahead of expectations; integration of RMG and RoentgenAnalytik acquisitions also proceeding to plan.

· Investment in R&D up 41% to £18.3 million with sustained momentum in new product introductions and strong new product pipeline.

· Interim dividend increased by 10.1% to 3.7 pence per share (2013: 3.36 pence).

*Adjusted numbers are stated to give a better understanding of the underlying business performance. Details of adjusting items can be found in Note 2.



Jonathan Flint, Chief Executive of Oxford Instruments plc, said "We will continue to focus on developing innovative new products and growing market share in our core areas of physical science. Our strategy will extend our reach into adjacent new markets by applying our tools and technologies to life science research and analysis, thus extending the reach and reputation of the Oxford Instruments brand worldwide."

----------------------------------------------------------------------------------------------

11 Nov Investec N/A Under Review
11 Nov Numis 1,350.00 Add
11 Nov N+1 Singer 1,350.00 Hold

Trading Statement
RNS
RNS Number : 8176C
Oxford Instruments PLC
22 January 2015



Release date: 7am 22nd January 2015

Oxford Instruments plc Quarter 3 Trading Update

22 January 2015



Oxford Instruments plc, a leading provider of high technology tools and systems for industry and research, today issues a Quarter 3 Trading Update which covers the period from 1st October 2014 to date.



In the third quarter organic orders and revenues were similar to the same period last year. In addition, Andor the acquisition made in the fourth quarter last year continues to perform well.



Significant orders, both taken in the year and forecast to be taken in Quarter 4, are for delivery to Russia. Recent tightening in the application of trade sanctions and, in particular the cancelling of certain export licences mean we no longer expect to convert theses orders to sales. We now assume that no sales can be made to Russia for the remainder of this year and we are also assuming no sales to Russia next year.



In addition, our forecast of recovery in the Japanese market has not yet occurred. The effects of Russia and Japan, combined with weaker trading in our short lead-time Industrial Analysis business means that, whilst we expect revenues for the second half to be ahead of the same period last year, we believe they will fall short of market expectations. We now anticipate adjusted profit before tax for the current year will be approximately £35 million.



In response to these challenges we are taking action to reduce costs and improve efficiency. Subject to consultation this may result in the closure of some sites and a reduction in headcount. This project aims to produce a cost saving of £6 million in the next financial year. The one off, cash costs of achieving these savings are expected to be in the region of £5 million which will be taken as an exceptional item in the current year.



Whilst it is not possible to predict when the situation in Russia will recover, order intake in Japan is improving. We expect to see the Group grow next year and beyond as we execute on our nanotechnology strategy.

Oxford Instruments (OXIG), down 27.95p, said in response to challenges in Russia and Japan it is taking action to reduce costs and improve efficiency, which could result in some site closures and reduction in headcount. It saw adjusted FY pretax profit at about £35m.

What a slapping!

2 Mar JP Morgan... 1,200.00 Overweight
2 Mar N+1 Singer 765.00 Hold

Acquisition
RNS
RNS Number : 9497L
Oxford Instruments PLC
01 May 2015





Release date: 1 May 2015



Oxford Instruments plc

Acquisition of Medical Imaging Resources, Inc.





Oxford Instruments plc, a leading provider of high technology tools and systems for industry and research, today announces the acquisition of Medical Imaging Resources, Inc. (MIR).



Founded in 1990 in Ann Arbor Michigan by CEO John Vartanian, MIR specialises in the build, lease and service of mobile medical imaging labs ("mobiles").



The mobile labs are built in MIR's factory, with Magnetic Resonance Imaging (MRI) and Computed Tomography (CT) systems from Siemens, GE, Philips and Toshiba. These are leased to customers across the USA. MIR is also responsible for servicing its mobiles. Customers include hospitals and clinics that need additional capacity or that wish to trial MRI or CT machines without committing to the infrastructure and cost associated with a permanent unit.



MIR will form a part of OIHealthcare, within the Group's Service sector, which already services GE MRI and CT machines in the USA. There are a number of synergies with OIHealthcare:



· This will be a significant step to making OIHealthcare a multi-skilled independent service provider able to support large individual service contracts;

· Access to OIHealthcare's parts and its purchasing power for complete systems will lower MIR's operating costs;

· There will be overheads savings in those areas where duplication is eliminated;

· MIR currently sub-contracts a significant portion of the service work for its mobiles. OIHealthcare staff are located in numerous states and once trained will take over the work and will be able to bring the margin in-house.



Consideration, which will be satisfied from existing facilities, comprises $10.4 million (c. £6.8 million) on completion followed by a further $10.1 million (c. £6.6 million) earn-out payable one year later. MIR has approximately $3.0 million (c. £2.0 million) net debt at completion.



In the year to 31 December 2014, MIR had sales of $16.6 million (c. £10.8 million), profit before tax of $2.8 million (c. £1.8 million) and EBITDA of $5.6 million (c. £3.6 million). At 31 December 2014, MIR had gross assets of $9.4 million (c. £6.1 million).







Jonathan Flint (Chief Executive) and Kevin Boyd (Finance Director) will host a conference call for analysts and investors on this announcement at 9:30 am (UK time), today 1 May. To join the call, please use the dial-in numbers below:



Dial: +44 (0)20 3139 4830

PIN: 89662683#







- Ends -

5 May Numis 1,150.00 Buy
5 May Beaufort... N/A Buy
5 May Jefferies... 990.00 Hold
5 May JP Morgan... 1,200.00 Overweight

29 May JP Morgan... 1,200.00 Overweight

Oxford Instruments, a leading provider of high technology tools and systems for industry and research, will announce its results for the year ended 31 March on 9 June.

JV for Oxford Instruments' Omicron business
RNS
RNS Number : 4609O
Oxford Instruments PLC
28 May 2015



For immediate release: 28 May 2015



Oxford Instruments plc

Oxford Instruments enters into Joint Venture with GD Intressenter AB, comprising Omicron Nanotechnology and Scienta Scientific



Oxford Instruments plc, a leading provider of high technology tools and systems for industry and research, today announces that it has entered into a Joint Venture with GD Intressenter AB of Sweden ("GDI") to create the world's largest player in the highly specialised Ultra High Vacuum Surface Science field. The JV will comprise Oxford Instruments' Omicron Nanotechnology GmbH and associated subsidiaries ("Omicron") and GDI's Scienta Scientific AB and associated subsidiaries ("Scienta").

In consideration for new shares in Scienta, Oxford Instruments has transferred all of its shares in the capital of Omicron to Scienta. Oxford Instruments holds a 47 per cent interest in the share capital of Scienta and GDI holds 53 per cent.

The JV provides excellent opportunities to enhance product development, cut production costs and broaden the product range, while extending market reach and strengthening customer relationships.

The Board of Directors of the JV will include representatives from GDI and Oxford Instruments. The CEO of the new business will be Mr Johan Åman who is based in Uppsala, Sweden. Mr Åman has been CEO of Scienta since 2013 and prior to this he held senior commercial and research positions in Mycronic AB. GDI is backed by a leading Nordic Venture Capital Firm, InnovationsKapital, and other financial investors.



In the twelve months to 31st March 2014, Omicron generated revenue of £28.5 million and a loss before tax of £0.6 million. The gross assets of Omicron at 30th September 2014 were £26.1 million. In the financial year to 31st December 2014, Scienta generated revenue of SEK279 million (approximately £24.6 million) and a profit before tax of SEK25 million (approximately £2.2 million). The gross assets of Scienta at 31st December 2014 were SEK146 million (approximately £12.9 million). Oxford Instruments has provided a term loan of SEK40 million (approximately £3.1 million) to the JV. The transaction will result in no profit or loss on the carrying value of Omicron for Oxford Instruments.



Commenting on the establishment of the JV, Jonathan Flint, Chief Executive of Oxford Instruments, stated:



"This new venture will create the largest player in the exciting field of Surface Science and UHV engineering. Customers will benefit from an enhanced product portfolio and improved service, and the synergies generated by merging the two businesses will provide significant efficiencies and cost savings."



Lars Hagdahl, Chairman of GDI and of the JV, said:

"I am very pleased with the creation of this JV. Going forward together we are a larger and stronger business that will be good for our customers, partners and employees."